Is it Time to Dump Portage Biotech Inc (PRTG) Stock After it Is Higher By 20.00% in a Week?

Overall market sentiment has been high on Portage Biotech Inc (PRTG) stock lately. PRTG receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Portage Biotech Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on PRTG!

See Full PRTG Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With PRTG Stock Today?

Portage Biotech Inc (PRTG) stock is trading at $4.08 as of 11:32 AM on Monday, Jun 5, a rise of $0.43, or 11.78% from the previous closing price of $3.65. The stock has traded between $3.65 and $4.40 so far today. Volume today is above average. So far 84,160 shares have traded compared to average volume of 19,630 shares.

More About Portage Biotech Inc

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others. Click Here to get the full Stock Report for Portage Biotech Inc stock.